CompletedNCT00146523
Mifepristone for psychotic symptoms in major depression
About this title
Read the official source — NCT00146523Researchers compared Mifepristone and placebo, tracking side effects to assess safety in people with depression.
Medication studyAges 18–75Multiple countries
Understand this study
What did researchers investigate?
Researchers compared Mifepristone and placebo, tracking side effects to assess safety in people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Sofia and 18 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMay 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 247
- Sponsor
- Corcept Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Bulgaria, Croatia, Romania, ...
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00146523
- Official title
Show the full official title
An International, Double-Blind, Placebo-Controlled, Study of the Efficacy and Safety of CORLUX™ (Mifepristone) vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Psychotic Major Depression (PMD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedSofia, Bulgaria · Varna, Bulgaria · Osijek, Croatia
8 more locations
- Rijeka, Croatia
- Split, Croatia
- Zagreb, Croatia
- Bucharest, Romania
- Târgu Mureş, Romania
- Belgrade, Serbia and Montenegro
- Kragujevac, Serbia and Montenegro
- Novi Sad, Serbia and Montenegro
Questions about this study
What did researchers investigate?
Researchers compared Mifepristone and placebo, tracking side effects to assess safety in people with depression.
Who is behind this study?
The study sponsor is Corcept Therapeutics.
Did this study involve medication?
Yes. The study involved medication, including Mifepristone and placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
